The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration during the week of April 25, 2016, a decision from the FDA is expected in early 2017. Additionally, an Expanded Access Program (EAP) in the United States for the investigational product, Lutathera, has begun at a few institutions across the country. Read more
